期刊文献+

超声波催化合成3-羟基-4-吡啶酮 被引量:1

Synthesis of Two 3-hydroxy-4-pyridinone Compounds Under Ultrasonic Irradiation
下载PDF
导出
摘要 在超声波催化条件下,麦芽酚与苄基氯、胺反应快速地合成了1,2-二甲基-3-羟基-4-吡啶酮和1-乙基-2-甲基-3-羟基-4-吡啶酮,目标产物经IR,1HNMR光谱表征,并与常规合成方法进行了比较,证明该方法使反应时间缩短,产率提高。 1,2-dimethyl-3-hydroxy-4-pyridinone and 1-ethyl-2-methyl-3-hydroxy-4-pyridinone were synthesized from 3-hydroxy-2-methyl-4-pyranone (maltol) and benzyl chloride through three steps of reactions under ultrasonic irradiation. 2-methyl-3-benzyloxy-4-pyranone (1),N-substituted-2-alkyl-3-benzyloxy-4-pyranone (2a,2b),N-substituted-2-alkyl-3-hydroxy-4-pyranone (3a,3b) were synthesized with moderate to high yields (40%~91.55%). The results show that comparing with the conventional thermal reaction,ultrasonic irradiation reaction enjoys very good activities for synthesizing pyridinone compounds. The target compounds were characterized by IR,1H NMR spectra.
出处 《科技导报》 CAS CSCD 2008年第3期44-45,共2页 Science & Technology Review
基金 全军“十五”指令性课题(3401040-OIL061)
关键词 羟基吡啶酮 超声波催化 合成 hydroxypyridinone ultrasonic catalysis synthesis
  • 相关文献

参考文献5

  • 1廖琪丽,胡文祥,周志明,王建营,程天民.羟基吡啶酮促排铀和钚的研究进展[J].中国药物化学杂志,2005,15(1):60-64. 被引量:3
  • 2Durbin P W, Kullgren B, Xu J, et al. New agents for in vivo chelation of uranium (Ⅵ): Efficacy and toxicity in mice of multidentate cathechalate and hydroxypyridinonate ligands [J]. Health Physics, 1997, 72 (6): 865- 879.
  • 3陈渝春,李兵.去铁酮和去铁胺联合治疗重症地中海贫血的安全性和有效性评估[J].微量元素与健康研究,2005,22(2):13-15. 被引量:5
  • 4Dobbin P S, Hider R C, Hall A D, et al. Synthesis, physicochemical properties and bialogical evaluation of N-substituted 2-Alkyl-3-hydroxy -4 (1H)-pyridinones: Orally active iron chelators with clinical potential [J]. Journal of Medicinal Chemistry, 1993, 36(17): 2448-2458.
  • 5Xu J, Durbin P W, Kullgren B, et al. Synthesis and initial evaluation for in vivo chelation of Pu(Ⅳ) of a mixed octadentate spermine-based ligand containing 4-Carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone and 6- Carbamoyl-1-hydroxy-2(1H)-pyridinone[J]. Journal of Medicinal Chemistry, 2002, 45: 3963-3971.

二级参考文献39

  • 1科·克勒尔.超铀元素化学[M].北京:原子能出版社,1977.230-231.
  • 2Liu G,Bruenge FW,Miller SC,et a1.Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(β-d—ribofuranosyl orpyranosyl)-4-pyridinone:potential iron overload drugs for oral administration[J].Bioorg Med Chem Lett,1998,8(21):3077—3080.
  • 3Henge-Napoli MH,Archimbaud M,Ansoborlo E,et a1.Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in rat after acute administration[J].Int Radiat Biol,1995,68(4):389—393.
  • 4Santos MA.Hydroxypyridinone complexes with aluminium.In vitro/vivo studies and perspectives[J].Coord Chem Rev,2002,228(2):187—203.
  • 5Li MS,Gu LQ,Huang ZS,et a1.Synthesis of 6-sub-stituted-3-hydroxy-4(1H)-pyridinones:oxidation-Michael addition of 3-hydroxy-4(1H)-pyridinones[J].Tetrahedron,1999,55(8):2237—2244.
  • 6Cohen SM,Xu J,Radkov E,et al.Syntheses and rdaxation properties of mixed gadolinium hydroxypyridimmate MRI contrastagents[J].Inorg Chem,2000,39(25):5747—5756.
  • 7Lopez R,Diaz Sylvester PL,Ubios AM,et a1.Percutaneous toxicity of uranyl nitrate:its effect in terms of exposure area and time[J].Health Phys,2000,78(4):434—437.
  • 8Chen J.Meyerhof DP,Tracy BL.Model results of kidney burdens from uraniuln intakes[J].Health Phys,2004,86(1):3—11.
  • 9Murray VSG,Bailey MR,Spratt BG.Depleted uraniurn:a new batthfield hazard[J].Lancet,2002,360(suppl.):31—32.
  • 10MillerAC,Stewart M,BrooksK,et a1.Depleted urnnium-catalyzed oxidative DNA damage:absence of significant alpha particle decay[J].J Inorg Biochem,2002,91(1):246—252.

共引文献6

同被引文献18

  • 1Santos M A,Marques M S,Chaves S. Hydroxypyridinones as "privileged" chelating structures for the design of medicinal drugs[J].COORDINATION CHEMISTRY REVIEWS,2012.240-259.
  • 2Kandioller W,Kurzwemhart A,Hanif M. Pyrone derivatives and metals:From natural products to metal-based drugs[J].Journal of Organometallic Chemistry,2011.999-1010.
  • 3Gama S,Dron P,Chaves S. A bis(3-hydroxy-4-pyridinone)-EDTA derivative as a strong chelator for M3 + hard metal ions:complexation ability and selectivity[J].Dalton Transactions,2009.6141-6150.
  • 4Santos M A. Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications mono and combined ligand approaches[J].COORDINATION CHEMISTRY REVIEWS,2008.1213-1224.
  • 5Santos M A,Gama S,Gano L. Bis (3-hydroxy-4-pyridinone)-EDTA derivative as a potential therapeutic Al-chelating agent.Synthesis,solution studies and biological assays[J].Journal of Inorganic Biochemistry,2005.1845-1852.
  • 6Santos M A. Hydroxypyridinone complexes with aluminium.In vitro/vivo studies and perspectives[J].COORDINATION CHEMISTRY REVIEWS,2002.187-203.
  • 7Xiao G,Hider R C,Dobbin P S. Structure-stability relationships of 3-hydroxypyridin-4-one complexes[J].Dalton Transactions,1992.3265-5371.
  • 8Grazina R,Gano L,Sebestik J. New tripodal hydroxypyridinone based chelating agents for Fe(Ⅲ),Al(Ⅲ) and Ga(Ⅲ):Synthesis,physico-chemical properties and bioevaluation[J].Journal of Inorganic Biochemistry,2009.262-273.
  • 9Clevette D J,Nelson W O,Nordin A. The complexation of aluminum with N-substituted 3-hydroxy-4-pyridinones[J].Inorganic Chemistry,1989.2079-2081.
  • 10Lang R,Polbom K,Severin T. Halfsandwich complexes of ruthenium (Ⅱ),rhodium (Ⅲ) and iridium (Ⅲ) with Nsubstituted 3-hydroxy-2-methyl-4-pyridone ligands[J].Inorganica Chimica Acta,1999.62-67.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部